Retrospective Study
Copyright ©The Author(s) 2020.
World J Hepatol. May 27, 2020; 12(5): 207-219
Published online May 27, 2020. doi: 10.4254/wjh.v12.i5.207
Table 3 Histopathological patterns, R ratios and Drugs/HDS in our study
Histopathological patternR ratioTotal, n = 38 (%)Drugs/HDS (n)
Hepatitis12 ± 0.418 (47.4)
Acute16 ± 0.15 (13.2)Nitrofurantoin (1)
Black cohosh1 (1)
Sertraline (1)
Lamotrigine (1)
Green tea extract (1)
Acute with extensive necrosis11 ± 3.38 (21.1)Diclofenac (1)
Acetaminophen (6)
Black cohosh1 (1)
Autoimmune-like6.2 ± 0.13 (7.9)Infliximab (2)
Isoniazid (1)
Chronic8.81 (2.6)Nitrofurantoin (1)
Non-necrotizing granulomatous hepatitis141 (2.6)BCG (1)
Cholestasis0.5 ± 0.15 (13.2)
Acute0.4 ± 0.54 (10.5)Ceftriaxone (1)
Methimazole (1)
Total parenteral nutrition (1)
Rivaroxaban (1)
Chronic0.81 (2.6)Triazolam and statin (1)
Cholestatic hepatitis9.0 ± 5.68 (21.1)Ezetimibe (1)
Cefazolin (1)
Hydroxycut2 (1)
Rizatriptan5 (1)
Methyldrostanolone (1)
Trimethobenzamide Hydrochloride5 (1)
Mesalamine (1)
C4 extreme3 (1)
Macrovesicular steatohepatitis1.4 ± 1.25 (13.2)Trimethoprim-sulfamethoxazole6 (1)
L-asparaginase (1)
Valproic acid (1)
Haart4 (1)
Amiodarone (1)
Mixed cholestatic hepatitis with steatosis and bile duct injury1.1 ± 0.82 (5.3)Dronedarone6 (1)
Hydroxycut26 (1)